Novartis UK has issued a statement specifying its disappointment at the initial decision by NICE to not recommend Mayzent (siponimod) for the treatment of secondary progressive multiple sclerosis with active disease.
Novartis UK has issued a statement specifying its disappointment at the initial decision by the National Institute for Health and Care Excellence (NICE) to not recommend Mayzent (siponimod) for the treatment of secondary progressive multiple sclerosis with active disease.
The Appraisal Consultation Document (ACD) published by NICE states that the committee does not recommend siponimod, within its marketing authorization, for the treatment of secondary progressive multiple sclerosis with active disease as a result of limited clinical evidence. Additionally, the committee notes that the “cost-effectiveness estimates are uncertain and none of the analyses reflect [its] preferred assumptions.”
In response to the recommendation, Novartis UK said, in a statement issued June 25, 2020, “We at Novartis UK are disappointed by the initial decision from the NICE not to recommend Mayzent (siponimod) for the treatment of secondary progressive multiple sclerosis (SPMS) with active disease, for routine use on the NHS [National Health Service]. Currently, treatment options for people diagnosed with SPMS with active disease are extremely limited and we believe siponimod addresses an unmet need in this patient population … If the initial decision from NICE remains unchanged patients will be denied access to the first licensed oral therapy for SPMS with active disease, leaving them without an effective, convenient treatment to manage their condition and help them maintain independence for longer. We are committed to continuing to work closely with NICE to address outstanding questions and data requirements in order to secure access as quickly as possible to siponimod for those patients in England and Wales that could benefit.”
The initial recommendation by NICE is now open for consultation and the final decision will follow a further appraisal, taking all comments into consideration. The deadline for the consultation period is July 16, 2020.
Sources: Novartis UK, NICE
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
How Smart Technology is Helping Reach Sustainability Goals in Drug Packaging
June 7th 2025Smart technologies, such as digital and laser printing, incorporated into manufacturing equipment are helping manufacturers align with sustainability goals, according to Sheikh Akbar Ali, general manager and head of Development and Technology for ACG Packaging Materials.
Market Demands and Emerging Technologies Shape Outsourcing Models
June 5th 2025Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving the nature of partnerships, but there are new types of partnerships gaining steam as well.